Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Primers 3, 63 (2023).
Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).
Gardin, A., Remih, K., Gonzales, E., Andersson, E. R. & Strnad, P. Modern therapeutic approaches to liver-related disorders. J. Hepatol. 76, 1392–1409 (2022).
Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).
Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015).
Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Ito, A., Kondo, S., Tada, K. & Kitano, S. Clinical development of immune checkpoint inhibitors. Biomed. Res. Int. 2015, 605478 (2015).
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Buchbinder, E. I. & Hodi, F. S. Immune-checkpoint blockade—durable cancer control. Nat. Rev. Clin. Oncol. 13, 77–78 (2016).
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379–401 (2019).
Brochez, L., Chevolet, I. & Kruse, V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur. J. Cancer 76, 167–182 (2017).
Guo, Y. et al. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials 276, 121018 (2021).
Singer, K., Gottfried, E., Kreutz, M. & Mackensen, A. Suppression of T-cell responses by tumor metabolites. Cancer Immunol. Immunother. 60, 425–431 (2011).
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312–319 (2005).
Phan, T. et al. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 27, 235–245 (2020).
Moreno, A. C. R. et al. The combined use of melatonin and an indoleamine 2,3-dioxygenase-1 inhibitor enhances vaccine-induced protective cellular immunity to HPV16-associated tumors. Front. Immunol. 9, 1914 (2018).
Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116–200ra116 (2013).
Alahdal, M., Xing, Y., Tang, T. & Liang, J. 1-Methyl-D-tryptophan reduces tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while enhances lymphocytes NF-κβ2, STAT3, and STAT4 pathways in murine pancreatic adenocarcinoma. Sci. Rep. 8, 9869 (2018).
Shang, K. et al. Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion. Oncol. Lett. 19, 3827–3838 (2020).
Wu, D. & Zhu, Y. Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer. Am. J. Transl. Res. 13, 1535–1547 (2021).
Yousef, Z. et al. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. J. Immunother. Cancer 9, e002057 (2021).
Kwiatkowska, I. et al. Assessment of an anticancer effect of the simultaneous administration of MM-129 and indoximod in the colorectal cancer model. Cancers 16, 122 (2024).
Johnson, T. S. et al. Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase I trial. Neuro-Oncol. 26, 348–361 (2023).
Briukhovetska, D. et al. Interleukins in cancer: from biology to therapy. Nat. Rev. Cancer 21, 481–499 (2021).
Starbeck-Miller, G. R., Xue, H.-H. & Harty, J. T. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J. Exp. Med. 211, 105–120 (2013).
Cirella, A. et al. Intratumoral gene transfer of mRNAs encoding IL12 in combination with decoy-resistant IL18 improves local and systemic antitumor immunity. Cancer Immunol. Res. 11, 184–198 (2023).
Wang, P. et al. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).
Nguyen, K. G. et al. Localized interleukin-12 for cancer immunotherapy. Front. Immunol. 11, 575597 (2020).
Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).
Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).
Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).
Wang, C., Zhang, Y. & Dong, Y. Lipid nanoparticle–mRNA formulations for therapeutic applications. Acc. Chem. Res. 54, 4283–4293 (2021).
Couvreur, P., Lepetre-Mouelhi, S., Garbayo, E. & Blanco-Prieto, M. J. Self-assembled lipid–prodrug nanoparticles. Nat. Rev. Bioeng. 1, 749–768 (2023).
Ding, C., Chen, C., Zeng, X., Chen, H. & Zhao, Y. Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy. ACS Nano 16, 13513–13553 (2022).
Delahousse, J., Skarbek, C. & Paci, A. Prodrugs as drug delivery system in oncology. Cancer Chemother. Pharmacol. 84, 937–958 (2019).
Yang, B., Gao, J., Pei, Q., Xu, H. & Yu, H. Engineering prodrug nanomedicine for cancer immunotherapy. Adv. Sci. 7, 2002365 (2020).
Kyu Shim, M., Yang, S., Sun, I.-C. & Kim, K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer immunotherapy: preclinical evidence for safe and effective drug delivery. Adv. Drug Deliv. Rev. 183, 114177 (2022).
Zhou, L. et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer. Nano Lett. 20, 4393–4402 (2020).
Shi, L., Lin, S., Zhou, F., Jiang, H. & Zhang, J. Recent advances in engineering prodrug-based nanomedicines for cancer therapy. Mater. Adv. 5, 4634–4659 (2024).
Tan, J. et al. Coordinating external and built-in triggers for tunable degradation of polymeric nanoparticles via cycle amplification. J. Am. Chem. Soc. 143, 13738–13748 (2021).
Mukalel, A. J. et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv. Funct. Mater. 34, 2312038 (2024).
Ding, Y., Dai, Y., Wu, M. & Li, L. Glutathione-mediated nanomedicines for cancer diagnosis and therapy. Chem. Eng. J. 426, 128880 (2021).
Wang, Q., Guan, J., Wan, J. & Li, Z. Disulfide based prodrugs for cancer therapy. RSC Adv. 10, 24397–24409 (2020).
Riley, J. L. PD-1 signaling in primary T cells. Immunol. Rev. 229, 114–125 (2009).
Del Vecchio, M. et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677–4685 (2007).
Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).
Okamura, H. et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378, 88–91 (1995).
Zhang, H. & Barz, M. Investigating the stability of RNA-lipid nanoparticles in biological fluids: unveiling its crucial role for understanding LNP performance. J. Control. Release 381, 113559 (2025).
Shelef, O., Gnaim, S. & Shabat, D. Self-immolative polymers: an emerging class of degradable materials with distinct disassembly profiles. J. Am. Chem. Soc. 143, 21177–21188 (2021).
Jain, R. et al. MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct. Nucleic Acid Ther. 28, 285–296 (2018).
Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).
Tang, L., Huang, Z., Mei, H. & Hu, Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct. Target. Ther. 8, 306 (2023).
Brito-Orama, S. & Sheth, R. A. The contemporary landscape and future directions of intratumoral immunotherapy. J. Immunother. Precis. Oncol. 6, 84–90 (2023).
De Lombaerde, E., De Wever, O. & De Geest, B. G. Delivery routes matter: safety and efficacy of intratumoral immunotherapy. Biochim. Biophys. Acta Rev. Cancer 1875, 188526 (2021).
Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607–625 (2024).
